New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Cullinan Therapeutics, Inc.

Contributing Author

Recent Articles by Cullinan Therapeutics, Inc.

Jan-08	Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones CGEM GlobeNewswire
Dec-08	Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting CGEM GlobeNewswire
Dec-01	Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia CGEM GlobeNewswire
Nov-10	Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting CGEM GlobeNewswire
Nov-06	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results CGEM GlobeNewswire
Nov-03	Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting CGEM GlobeNewswire
Oct-25	Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 CGEM GlobeNewswire
Sep-12	Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum CGEM GlobeNewswire
Aug-21	Cullinan Therapeutics to Participate in Upcoming Investor Conferences CGEM GlobeNewswire
Aug-07	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results CGEM GlobeNewswire
Jun-04	Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases CGEM GlobeNewswire
May-29	Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference CGEM GlobeNewswire
May-08	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results CGEM GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.